KZR-540 is a novel oral small molecule inhibitor of Sec61 cotranslational translocation that potently and selectively blocks PD-1 expression

Cristina Delgado-Martin, Neel K. Anand, Janet L. Anderl, Chengguo Dong, R. Andrea Fan, Ying Fang, Christopher J. Kirk, Tony Muchamuel, Yu Qian, Jinhai Wang, Jennifer A. Whang, Patricia Zuno-Mitchell Kezar Life Sciences, South San Francisco, CA, United States

KEZAR



Tumor efficacy assessment was performed in huPD-1 mice bearing human PD-L1 MC38 colon carcinoma cells. Mice were treated daily with KZR-540 PO or twice weekly with 10 mg/kg Keytruda™ (anti-PD-1 antibody) IV for 21 days, and tumor volume and body weight were monitored 3 times per week. Tumors and tumor draining lymph nodes (tdLN) were collected at the end of the study, and PD-1 surface expression was measured on live T cells by FC

One-way ANOVA was used for statistical analysis (*p<0.5, **p<0.01, ***p<0.001, ****p<0.0001 compared to vehicle group)



melanoma cells with human T cells in the presence of KZR-540 increases T cell-dependent cell death

> 111 333 1000 »M 1/7D 540

III No T cells

T cells

Presented at SITC 37th Annual Meeting • Boston, Massachusetts• November 8-12, 2022

In this model, KZR-540 performance is comparable to that of a commercially

References

Maifeld SV, MacKinnon AL, Garrison JL, et. al. Chem Biol. 2011: 18: 1082-1088.

available biologic anti-PD-1 agent.

Lowe, et al. ASH Annual Meeting 2019, Abstract 408

Lowe, et al. ASCO Annual Meeting 2020. Abstract 3582